Literature DB >> 24556928

Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice.

Aidar R Gosmanov1, Jim Wan.   

Abstract

BACKGROUND: Positive predictive value (PPV) of hemoglobin A1c (HbA1c) for diagnosis of prediabetes in clinical practice has not been well studied.
METHODS: In a prospective study, patients diagnosed with prediabetes based on HbA1c (5.7%-6.4%) underwent a 75-g oral glucose tolerance test (OGTT) as the gold standard test to diagnose dysglycemia. Demographics, anthropometrics, comorbidity, concomitant prescription medications and biochemical data were collected.
RESULTS: We identified 66 patients with HbA1c-based prediabetes with a mean HbA1c of 6.00 ± 0.20%. However, based on the OGTT, 32 had normal glucose tolerance (NGT), 26 had prediabetes and 8 had diabetes yielding a PPV of HbA1c of 39.4%. In univariate analysis, the patients with the OGTT-based prediabetes administered more medications for associated medical problems compared with the NGT group (5.9 ± 2.2 versus 2.6 ± 1.8, P < 0.0001). After adjustment for baseline variables, the medication use remained significantly different between OGTT-based prediabetes and NGT groups (P = 0.041).
CONCLUSIONS: PPV of HbA1c for diagnosis of prediabetes in clinical setting is low. Patients with HbA1c of 5.7% to 6.4% should undergo OGTT to confirm diagnosis of dysglycemia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24556928     DOI: 10.1097/MAJ.0000000000000223

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  15 in total

1.  Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events.

Authors:  Naveen Rathi; Paul K Whelton; Glenn M Chertow; William C Cushman; Alfred K Cheung; Guo Wei; Robert Boucher; Paul L Kimmel; Adam P Bress; Holly J Kramer; Catreena Al-Marji; Tom Greene; Srinivasan Beddhu
Journal:  Am J Hypertens       Date:  2019-11-15       Impact factor: 2.689

Review 2.  Prediabetes diagnosis and treatment: A review.

Authors:  Nidhi Bansal
Journal:  World J Diabetes       Date:  2015-03-15

Review 3.  Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.

Authors:  Bianca Hemmingsen; Gabriel Gimenez-Perez; Didac Mauricio; Marta Roqué I Figuls; Maria-Inti Metzendorf; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2017-12-04

Review 4.  Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.

Authors:  Bianca Hemmingsen; David Peick Sonne; Maria-Inti Metzendorf; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2016-10-17

Review 5.  Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.

Authors:  Bianca Hemmingsen; Jesper Krogh; Maria-Inti Metzendorf; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2016-04-21

Review 6.  Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.

Authors:  Bianca Hemmingsen; David P Sonne; Maria-Inti Metzendorf; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2017-05-10

7.  Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.

Authors:  Kasper S Madsen; Yuan Chi; Maria-Inti Metzendorf; Bernd Richter; Bianca Hemmingsen
Journal:  Cochrane Database Syst Rev       Date:  2019-12-03

8.  Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.

Authors:  Suzanne Vl Moelands; Peter Lbj Lucassen; Reinier P Akkermans; Wim Jc De Grauw; Floris A Van de Laar
Journal:  Cochrane Database Syst Rev       Date:  2018-12-28

9.  Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.

Authors:  Emil Ørskov Ipsen; Kasper S Madsen; Yuan Chi; Ulrik Pedersen-Bjergaard; Bernd Richter; Maria-Inti Metzendorf; Bianca Hemmingsen
Journal:  Cochrane Database Syst Rev       Date:  2020-11-19

10.  Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.

Authors:  Bernd Richter; Bianca Hemmingsen; Maria-Inti Metzendorf; Yemisi Takwoingi
Journal:  Cochrane Database Syst Rev       Date:  2018-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.